Zertuche-Martínez Zertuche-Martínez

Dr. Zertuche-Martínez Zertuche-Martínez

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
KGKARINA GONZÁLEZ GARCÍA
KARINA GONZÁLEZ GARCÍA
ALArmando López-Martínez
Armando López-Martínez
Juan Manuel Velázquez-EnríquezJuan Manuel Velázquez-Enríquez
Juan Manuel Velázquez-Enríquez
ZZZertuche-Martínez Zertuche-Martínez
Zertuche-Martínez Zertuche-Martínez
GTGABRIELA CARRASCO TORRES
GABRIELA CARRASCO TORRES
Verónica Rocío Vásquez-GarzónVerónica Rocío Vásquez-Garzón
Verónica Rocío Vásquez-Garzón
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease characterized by parenchymal scarring, leading progressively to alveolar architecture distortion, respiratory failure, and eventually death. Currently, there is no effective treatment for IPF. Previously, 3′5-dimaleamylbenzoic acid (3′5-DMBA), a maleimide, demonstrated pro-apoptotic, anti-inflammatory, and anti-cancer properties; however, its potential therapeutic effects on IPF have not been addressed. Bleomycin (BLM) 100 U/kg was administered to CD1 mice through an osmotic minipump. After fourteen days of BLM administration, 3′5-DMBA (6 mg/kg or 10 mg/kg) and its vehicle carboxymethylcellulose (CMC) were administered intragastrically every two days until day 26. On day 28, all mice were euthanized. The 3′5-DMBA effect was assessed by histological and immunohistochemical staining, as well as by RT-qPCR. The redox status on lung tissue was evaluated by determining the glutathione content and the GSH/GSSG ratio. 3′5-DMBA treatment re-established typical lung histological features and decreased the expression of BLM-induced fibrotic markers: collagen, α-SMA, and TGF-β1. Furthermore, 3′5-DMBA significantly reduced the expression of genes involved in fibrogenesis. In addition, it decreased reduced glutathione and increased oxidized glutathione content without promoting oxidative damage to lipids, as evidenced by the decrease in the lipid peroxidation marker 4-HNE. Therefore, 3′5-DMBA may be a promising candidate for IPF treatment.

30 June 2026 in Biology
Verified
Journal Article
Open access
PDF file
RBRafael Baltiérrez-Hoyos
Rafael Baltiérrez-Hoyos
Juan Manuel Velázquez-EnríquezJuan Manuel Velázquez-Enríquez
Juan Manuel Velázquez-Enríquez
JSJovito Santos
Jovito Santos
DGDulce Natividad Jiménez Gómez
Dulce Natividad Jiménez Gómez
AHAlma Aurora Ramírez Hernández
Alma Aurora Ramírez Hernández
Verónica Rocío Vásquez-GarzónVerónica Rocío Vásquez-Garzón
Verónica Rocío Vásquez-Garzón
Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease characterized by high mortality and marked clinical heterogeneity. A defining yet insufficiently understood feature of IPF is its frequent coexistence with pulmonary and extrapulmonary comorbidities. However, the molecular basis that underlies this multisystem involvement remains unclear. We applied an integrative systems-level framework that combines lung-derived transcriptomic datasets with curated disease–gene associations across major IPF-associated comorbidities. Network organization and functional stratification analyses were used to characterize shared and disease-specific molecular modules, and independent transcriptomic datasets were analyzed to evaluate the consistency of these patterns. These analyses revealed structured molecular convergence between IPF and its comorbidities organized into two interacting biological programs: a lung-enriched fibrotic–mechanical program and a systemically distributed neuroimmune–metabolic program. These programs are interconnected through a shared regulatory interface that includes IL6, AKT1, TGFB1 and STAT3. This organization was consistently observed across independent datasets. IPF emerges from the interaction between pulmonary and systemic regulatory programs rather than isolated lung-restricted mechanisms. This framework provides a basis for understanding disease heterogeneity and comorbidity burden, with potential implications for stratification and therapeutic targeting.

11 July 2026 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
KGKARINA GONZÁLEZ GARCÍA
KARINA GONZÁLEZ GARCÍA
GJGalilea Guadalupe Jimenez-Jacinto
Galilea Guadalupe Jimenez-Jacinto
ZZZertuche-Martínez Zertuche-Martínez
Zertuche-Martínez Zertuche-Martínez
Claudia Rangel-EscareñoClaudia Rangel-Escareño
Claudia Rangel-Escareño
AJAriadna Jalife-Gómez
Ariadna Jalife-Gómez
Verónica Rocío Vásquez-GarzónVerónica Rocío Vásquez-Garzón
Verónica Rocío Vásquez-Garzón